Aplastic Anemia

Table of Contents

  1. What is Aplastic Anemia?
  2. Classification and Severity
  3. Causes and Risk Factors
  4. Symptoms
  5. Diagnosis and Lab Tests
  6. Conventional Treatment
  7. Nutritional and Supportive Approaches
  8. Complications
  9. Prognosis
  10. Prevention
  11. Key Research Papers
  12. Connections
  13. Featured Videos

What is Aplastic Anemia?

Aplastic anemia is a life-threatening bone marrow failure syndrome in which the bone marrow stops producing enough new blood cells across all three major lineages — red blood cells (RBCs), white blood cells (WBCs), and platelets. This simultaneous failure of all three cell lines is called pancytopenia, and it is the defining feature that separates aplastic anemia from ordinary anemia, which affects only red cells.

Under normal conditions, the bone marrow contains hematopoietic stem cells (HSCs) — master cells capable of generating every type of blood cell the body needs. In aplastic anemia, these stem cells are either destroyed, severely depleted, or suppressed. What remains is largely a fatty, hypocellular marrow incapable of meeting the body's daily demand for roughly 200 billion new blood cells. Without treatment, severe aplastic anemia is uniformly fatal within months.

The name is somewhat misleading: "aplastic" refers to the failure of the bone marrow itself (from Greek aplasia, meaning absence of development), not simply a shortage of red cells. The anemia — fatigue, pallor, breathlessness — is only one dimension of the problem. The simultaneous absence of white cells leaves patients vulnerable to devastating infections, and the loss of platelets triggers dangerous bleeding.

Aplastic anemia is rare but not vanishingly so. In Western countries the incidence is approximately 2–3 cases per million people per year. In East and Southeast Asia — Japan, Thailand, China — rates are notably higher at 3–7 cases per million per year, a difference that may reflect genetic susceptibility differences, environmental exposures, or both. The disease follows a bimodal age distribution: it peaks in young adults aged 15–25 years, then rises again in people older than 60. The reasons for this pattern are not fully understood, but the younger peak is thought to reflect the autoimmune mechanisms most common in acquired aplastic anemia, while the older peak may involve both immune dysregulation and the accumulation of somatic mutations in aging bone marrow.

With modern treatment — hematopoietic stem cell transplantation for eligible patients and immunosuppressive therapy for others — long-term survival has improved dramatically over the past four decades. For young patients with a matched sibling donor, cure rates now exceed 80–90%. The challenge remains for older patients, those without suitable donors, and those who relapse or develop clonal complications.

Back to Table of Contents

Classification and Severity

Aplastic anemia is classified along two axes: severity (which drives treatment urgency) and etiology (acquired versus inherited), which shapes long-term management.

Severity Classification

Moderate (Non-Severe) Aplastic Anemia: The patient has cytopenias in one or more cell lines with a hypocellular bone marrow, but the blood counts do not fall low enough to meet the criteria for severe disease. These patients may be watched carefully or treated with androgens or eltrombopag while awaiting spontaneous improvement, though many eventually progress to severe disease.

Severe Aplastic Anemia (SAA): Defined by the Camitta criteria (1976, still in use) as bone marrow cellularity below 25% (or 25–50% with fewer than 30% residual hematopoietic cells), plus at least two of the following three peripheral blood criteria:

SAA represents an immediate medical emergency. Without treatment, most patients die within 6–12 months from infection or hemorrhage.

Very Severe Aplastic Anemia (VSAA): A subgroup of SAA defined by an ANC below 0.2 × 10&sup9;/L. Patients with VSAA have virtually no functioning neutrophils and face the highest early mortality. They require immediate intensive treatment and have somewhat worse outcomes with immunosuppression than patients with ANC 0.2–0.5.

Etiological Classification

Acquired Aplastic Anemia accounts for the vast majority of cases. Most are idiopathic — no clear cause can be identified even after careful testing. A smaller subset are linked to specific triggers: drugs, chemicals, infections, or autoimmune conditions.

Inherited (Constitutional) Aplastic Anemia encompasses several genetic syndromes:

Distinguishing acquired from inherited aplastic anemia is critically important before treatment because the conditioning regimens, donor selection criteria, and long-term surveillance differ substantially. Chromosome breakage studies (for Fanconi anemia) and telomere length testing should be performed in all patients younger than 40 — and in older patients when clinical suspicion exists — before starting immunosuppression.

Back to Table of Contents

Causes and Risk Factors

In approximately 70–80% of acquired cases, no definitive cause is found. These idiopathic cases are now understood to be predominantly autoimmune in mechanism, even when no trigger is identified. In the remaining cases, a precipitating factor can often be traced.

Autoimmune Mechanism (Idiopathic Cases)

The dominant theory — supported by decades of clinical observation and laboratory evidence — is that autoreactive cytotoxic T lymphocytes (CD8+ T cells) attack and destroy hematopoietic stem cells. These T cells produce interferon-gamma and TNF-alpha, which suppress hematopoiesis and trigger apoptosis of stem cells. The best evidence for this model is that immunosuppressive therapy (which eliminates or suppresses these T cells) rescues most patients. In research settings, oligoclonal T-cell expansions directed against specific stem cell antigens have been documented. PNH clones (cells lacking GPI-anchored proteins, which are resistant to complement attack) frequently emerge in the surviving stem cell pool — this is thought to confer a selective survival advantage when the immune attack targets GPI-anchored surface proteins.

Drugs

Chemicals and Environmental Toxins

Viral Infections

Radiation

Exposure to ionizing radiation — from nuclear accidents, therapeutic radiation to the pelvis or spine, or occupational exposure — directly destroys hematopoietic stem cells in a dose-dependent fashion. The bone marrow is among the most radiosensitive tissues in the body.

Other Causes

Back to Table of Contents

Symptoms

The symptoms of aplastic anemia reflect the consequences of losing all three cell lines simultaneously. Unlike other anemias, where fatigue alone dominates, aplastic anemia typically presents with a triad of overlapping symptom clusters — each driven by a different missing cell type.

Symptoms of Anemia (Low Red Blood Cells)

Symptoms of Thrombocytopenia (Low Platelets)

Symptoms of Leukopenia (Low White Blood Cells)

What is Absent

Aplastic anemia typically does not cause splenomegaly (an enlarged spleen). The absence of splenomegaly is an important clinical clue that distinguishes aplastic anemia from other causes of pancytopenia — including myelofibrosis, lymphoma infiltrating the marrow, and hypersplenism — where the spleen is often enlarged because it is being used as a blood-cell-producing organ (extramedullary hematopoiesis) or is trapping and destroying cells. The lymph nodes are also generally normal in aplastic anemia.

Back to Table of Contents

Diagnosis and Lab Tests

The diagnosis of aplastic anemia requires integrating peripheral blood findings, bone marrow examination, and targeted testing to exclude other causes of pancytopenia. No single test is sufficient — the bone marrow biopsy is essential.

Complete Blood Count (CBC)

The CBC typically shows pancytopenia: low hemoglobin, low platelet count, and low white blood cell count with a particularly low absolute neutrophil count. The mean corpuscular volume (MCV) may be slightly elevated (macrocytosis) due to stress erythropoiesis in the residual marrow, but the red cells are generally normocytic and normochromic — neither the microcytic/hypochromic pattern of iron deficiency nor the macrocytic pattern of B12/folate deficiency.

Peripheral Blood Smear

Examination of the peripheral blood smear is critical. In aplastic anemia, the smear shows:

Reticulocyte Count

The reticulocyte count (immature red blood cells released from bone marrow) is characteristically low or absent — reflecting the failure of the marrow to produce new red cells. An elevated reticulocyte count would suggest a hemolytic process (where marrow is working hard to compensate for destruction of cells), not aplastic anemia.

Bone Marrow Biopsy (Essential)

The bone marrow biopsy is the cornerstone of diagnosis and cannot be replaced by any blood test. In aplastic anemia it shows:

Bone Marrow Aspirate

Often yields scant material ("dry tap") or sparse cellular material. What can be obtained may show lymphocytes and plasma cells with markedly reduced or absent hematopoietic precursors. The aspirate alone is insufficient — the biopsy is required to assess overall cellularity.

Cytogenetics (Chromosome Analysis)

Cytogenetic testing of bone marrow cells is essential to exclude myelodysplastic syndrome (MDS), which can present identically to aplastic anemia on clinical grounds but shows chromosomal abnormalities (monosomy 7, deletion 5q, trisomy 8, and others). The presence of chromosomal abnormalities argues strongly for MDS rather than aplastic anemia — an important distinction because the treatment approaches differ.

Flow Cytometry — PNH Clone

Flow cytometry to detect a paroxysmal nocturnal hemoglobinuria (PNH) clone should be performed in all patients with aplastic anemia. PNH clones (cells lacking GPI-anchored surface proteins CD55 and CD59) are found in approximately 30–50% of aplastic anemia patients and carry prognostic significance. A significant PNH clone (greater than 10% of granulocytes) confirms the autoimmune pathophysiology, predicts a higher likelihood of response to immunosuppressive therapy, and identifies patients at risk for future hemolytic PNH or thrombotic events. Patients with large PNH clones may need eculizumab (an anti-C5 complement inhibitor) if they develop clinically significant PNH.

Telomere Length Testing

Telomere length should be measured (typically by flow cytometry-FISH) in all aplastic anemia patients, particularly those under 40 and those with a family history of early-onset marrow failure, pulmonary fibrosis, or liver disease. Very short telomeres (below the 10th percentile) point toward an inherited telomere biology disorder (dyskeratosis congenita or related conditions), which significantly alters management — these patients may respond partially to androgens (danazol) rather than standard immunosuppression and require modified HSCT conditioning.

Chromosome Breakage Testing

All patients under 40 should be tested for Fanconi anemia by exposing lymphocytes to DNA crosslinking agents (diepoxybutane, DEB, or mitomycin C, MMC). Cells from Fanconi anemia patients show characteristically elevated rates of chromosome breakage and radial figures. Fanconi anemia patients cannot tolerate standard conditioning regimens for HSCT (which use alkylating agents) and require reduced-intensity protocols; standard immunosuppression is ineffective.

Other Tests

Back to Table of Contents

Conventional Treatment

Treatment of aplastic anemia has two fundamental goals: replace or rescue the bone marrow, and provide supportive care while this is achieved. The choice of definitive therapy depends critically on the patient's age, disease severity, and the availability of a matched stem cell donor.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — Potentially Curative

HSCT is the only curative treatment for aplastic anemia. It replaces the failed bone marrow with healthy donor stem cells capable of producing all blood cell lineages normally and permanently.

Matched Sibling Donor (MSD) HSCT: The gold standard. Young patients (under 40) with a matched sibling donor — roughly 25–30% of patients will have one — should proceed to HSCT as first-line definitive therapy without attempting immunosuppression first. Long-term survival exceeds 80–90% in centers experienced with this procedure. The conditioning regimen typically uses cyclophosphamide plus antithymocyte globulin (ATG) to ablate the recipient's immune system before infusing donor cells.

Matched Unrelated Donor (MUD) HSCT: For patients without a matched sibling, a matched unrelated donor from registries (Be The Match, DKMS) can be used. Outcomes have improved substantially with better HLA matching (10/10 allele-level) and refined conditioning regimens, with survival rates approaching 70–80% in younger patients. Graft-versus-host disease (GVHD) rates are higher than with sibling donors.

Cord Blood and Haploidentical Transplants: Emerging options for patients without a fully matched donor, using post-transplant cyclophosphamide-based platforms to control GVHD. Results are improving but still lag behind matched sibling outcomes.

Immunosuppressive Therapy (IST) — First-Line for Non-Transplant Candidates

Patients who are older than 40, lack a suitable donor, or have significant comorbidities are treated with immunosuppression, which eliminates the autoreactive T cells driving stem cell destruction and allows residual hematopoietic stem cells to recover.

Standard Regimen — Horse ATG + Cyclosporine A + Eltrombopag:

Response to IST is not immediate — it typically takes 3–6 months to see meaningful blood count recovery. Patients require intensive supportive care during this period.

Second-Line and Refractory Disease: Patients who fail first-line IST may be offered rabbit ATG + cyclosporine, HSCT from an alternative donor, or investigational agents. Eltrombopag as a single agent has shown activity in some refractory patients.

Androgens

Synthetic androgens — danazol and oxymetholone — have modest activity in aplastic anemia, particularly in moderate (non-severe) disease and in patients with short telomeres (where they stimulate telomerase activity). They are not used as monotherapy in SAA but may be added as adjuncts in refractory or relapsed cases. Side effects include liver toxicity, virilization in women, and accelerated bone age in children.

Hematopoietic Growth Factors

G-CSF (granulocyte colony-stimulating factor) and erythropoietin play a limited role as primary therapy. G-CSF may temporarily boost neutrophil counts during life-threatening infections while waiting for definitive treatment to take effect. It is not used routinely as monotherapy for aplastic anemia.

Supportive Care

Back to Table of Contents

Nutritional and Supportive Approaches

Nutritional and lifestyle approaches do not treat aplastic anemia directly — no supplement reverses bone marrow failure. However, they play a meaningful role in supporting patients through intensive treatment, reducing infection risk, preventing deficiencies, and improving quality of life during recovery.

Neutropenic Diet During Severe Neutropenia

When the absolute neutrophil count falls below 0.5 × 10&sup9;/L — a threshold at which the immune system cannot fight off ordinary bacteria and fungi — patients are often placed on a neutropenic diet to minimize exposure to foodborne pathogens. Practical guidelines include:

The evidence base for strict neutropenic diet protocols is actually mixed — large studies have not consistently shown benefit over standard food safety practices — but the principle of avoiding high-risk raw foods during severe immunosuppression is broadly endorsed by transplant centers.

Antifungal-Targeted Diet Precautions

Invasive aspergillosis is a major cause of death in aplastic anemia. While antifungal medications (posaconazole, voriconazole) are the primary protection, patients in the home environment are sometimes advised to minimize exposure to mold sources: avoiding gardening and soil work, avoiding indoor plants (high mold counts in potting soil), and staying away from construction sites and hay.

Immune-Supporting Micronutrients

Malnutrition is common in aplastic anemia patients due to poor appetite, mouth sores from immunosuppressive treatment, and frequent infections. Correcting common nutritional deficiencies supports immune function and recovery:

Avoiding Ongoing Toxin Exposure

For patients whose aplastic anemia may have been triggered by environmental or occupational exposures, removing the trigger is essential:

Caloric and Protein Support

Patients undergoing HSCT or intensive immunosuppression often experience significant weight loss, mucositis, and nausea. Adequate protein intake (1.2–1.5 g/kg/day) supports immune recovery and tissue repair. Nutritional support — oral supplements, and in some cases nasogastric feeds or parenteral nutrition — may be required during the most intensive phases of treatment.

Back to Table of Contents

Complications

Aplastic anemia carries serious short- and long-term complications — many arising from the disease itself, others from its treatments.

Bleeding and Hemorrhage

Severe thrombocytopenia creates constant risk of bleeding. Minor bleeds — bruising, gum bleeding, nosebleeds — are constant companions. Life-threatening bleeding events include intracranial hemorrhage, which is one of the leading causes of early death in untreated or refractory aplastic anemia. Gastrointestinal bleeding and pulmonary hemorrhage are also serious risks when platelet counts fall below 10 × 10&sup9;/L.

Infections

Severe neutropenia leaves patients defenseless against bacterial and fungal pathogens that healthy individuals clear effortlessly. Invasive fungal infections — particularly Aspergillus — are among the most feared complications, carrying mortality rates of 30–60% even with antifungal therapy. Bacteremia from gram-negative organisms (Pseudomonas, Klebsiella, E. coli) and gram-positive organisms (staphylococci, streptococci) is the other major infectious threat. Infections are a leading cause of treatment-related death during the neutropenic period before bone marrow recovery.

Clonal Evolution to MDS or AML

Perhaps the most sobering long-term complication of aplastic anemia treated with immunosuppression is the risk of the residual stem cell population developing clonal abnormalities. Approximately 10–15% of IST-treated patients develop myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) within 10 years of treatment. This risk is lower after successful HSCT. Several somatic mutations found in aplastic anemia clones (DNMT3A, ASXL1, RUNX1, BCOR/BCORL1) are now recognized as early markers of clonal evolution, and their presence has prognostic significance. Monosomy 7, detected by cytogenetic surveillance, is particularly ominous as it predicts transformation to MDS with aggressive behavior.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

As noted above, PNH clones are found in 30–50% of aplastic anemia patients. In most, the clone remains small and clinically silent. However, in some patients — especially those whose aplastic anemia responds to immunosuppression — the PNH clone expands over years, leading to clinically significant PNH with hemolytic anemia, thrombosis (in unusual locations — hepatic, mesenteric, cerebral veins), and cytopenias. The complement inhibitor eculizumab (and its successor ravulizumab) dramatically reduces hemolysis and thrombosis risk in patients with clinically significant PNH.

Iron Overload

Patients who require months to years of red cell transfusions accumulate iron at roughly 200–250 mg per unit of packed red cells — iron that the body has no mechanism to excrete. Over time, iron deposits in the liver (fibrosis, cirrhosis), heart (cardiomyopathy, arrhythmias), and endocrine organs (diabetes, hypothyroidism, hypogonadism). Iron chelation therapy (deferasirox, most commonly) is the standard approach when ferritin rises substantially.

Complications of HSCT

Cyclosporine-Related Complications

Long-term cyclosporine use causes nephrotoxicity (rising creatinine, hypertension, renal tubular damage), neurotoxicity (tremor, headache), gingival hyperplasia, and hypertrichosis. Renal function must be monitored regularly, and cyclosporine doses adjusted to maintain therapeutic levels while avoiding excessive toxicity.

Back to Table of Contents

Prognosis

The prognosis of aplastic anemia has been transformed over the past 40 years. What was once a disease with near-universal mortality in severe forms is now, for many patients, a manageable or curable condition — though serious risks remain, especially in older patients and those without matched donors.

Without Treatment

Untreated severe aplastic anemia is rapidly fatal. Historical data from the pre-treatment era showed that nearly 100% of patients with SAA died within 1 year, most within the first few months, from overwhelming infection or hemorrhage. This stark reality underscores the urgency of rapid diagnosis and treatment initiation.

With Allogeneic HSCT (Matched Sibling)

For young patients (under 40) with a matched sibling donor who receive HSCT as first-line therapy, long-term overall survival exceeds 80–90% at experienced centers. Five-year event-free survival (no relapse, no secondary malignancy, no graft failure) approaches 85–90% in optimal cases. Older patients (40–60) have somewhat lower survival, and patients over 60 have significantly higher transplant-related mortality due to GVHD, infections, and organ toxicity from conditioning.

With Immunosuppressive Therapy (IST)

For patients treated with standard h-ATG + cyclosporine + eltrombopag:

Prognostic Factors

Back to Table of Contents

Prevention

Primary prevention of aplastic anemia is possible for a subset of cases where a known trigger can be identified and avoided, but the majority of cases (idiopathic, autoimmune-mediated) currently have no known preventable cause.

Avoiding Known Chemical Triggers

Judicious Use of High-Risk Medications

Chloramphenicol should be reserved for infections with no effective alternative treatment — its convenience does not justify its risk when other antibiotics are available. Phenylbutazone has been removed from most markets for this reason. Patients prescribed drugs with known aplastic anemia associations (carbamazepine, felbamate) should be counseled about early warning signs and have baseline and periodic CBCs.

Radiation Safety

Avoiding unnecessary ionizing radiation exposure — using radiation-shielding precautions in medical settings, adhering to occupational exposure limits — reduces the risk of radiation-induced marrow damage. Therapeutic radiation to fields overlying the spine, pelvis, or long bones (which contain significant marrow) requires careful dose planning to minimize marrow toxicity.

Monitoring of High-Risk Inherited Conditions

Patients with known inherited aplastic anemia predisposition syndromes — Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome — should be followed prospectively with regular CBCs and annual bone marrow evaluations to detect aplastic anemia and clonal evolution early, before life-threatening complications develop. Early HSCT planning in these patients, while counts are still acceptable, leads to significantly better outcomes than emergency transplantation during crisis.

No Proven Primary Prevention for Idiopathic Cases

For the 70–80% of acquired aplastic anemia cases that are idiopathic, there is currently no established primary prevention strategy. Research into the specific autoantigens driving T-cell attack, and into genetic susceptibility variants that predispose to autoimmune bone marrow failure, may eventually lead to preventive strategies — but these remain areas of active investigation.

Back to Table of Contents

Key Research Papers

  1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-19. PMID 16778145. DOI 10.1182/blood-2006-03-010777
  2. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-96. PMID 22517900. DOI 10.1182/blood-2011-12-274019
  3. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540-1550. PMID 28423296. DOI 10.1056/NEJMoa1613878
  4. Dezern AE, Brodsky RA. Clinical management of aplastic anemia. Expert Rev Hematol. 2011;4(2):221-30. PMID 21495932. DOI 10.1586/ehm.11.15
  5. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428-1436. PMID 28159741. DOI 10.1182/blood-2016-08-693481
  6. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70. PMID 19673883. DOI 10.1111/j.1365-2141.2009.07842.x
  7. Yoshida N, Yagasaki H, Hama A, et al. Predicting response and avoiding toxicity in anti-thymocyte globulin (ATG)-based treatment for aplastic anemia. Int J Hematol. 2020;111(5):626-637. PMID 32270419
  8. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361(24):2353-65. PMID 20007561. DOI 10.1056/NEJMra0903373
  9. Risitano AM, Maciejewski JP. Current and future treatments for aplastic anemia. Expert Rev Hematol. 2011;4(1):57-72. PMID 21322387
  10. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373(1):35-47. PMID 26132940. DOI 10.1056/NEJMoa1414799

PubMed topic searches:

Back to Table of Contents

Connections

Back to Table of Contents